"Tysabri is being positioned correctly now by Biogen as JC negative patients who are declining. So, even if you start off an oral or another indication in a JC negative declined, MS or Tysabri is by far the best alternative for patients. So we believe that Tysabri will stay in that position, Biogen now has a P&L incentive as oppose to a disincentive in some ways to position it aggressively and properly for that group of patients. And if you take the denominator of the million treated patients around the world and 400 million plus or minus JC negative."
http://www.earningsimpact.com/Trans...--Jefferies-2013-Global-Healthcare-Conference
http://www.earningsimpact.com/Trans...--Jefferies-2013-Global-Healthcare-Conference